The Novartis pharmaceutical firm has announced plans to buy back as much as $15 billion (CHF12.88 billion) in shares as it prepares to spin off its Sandoz generics unit.
This content was published on
2 minutes
Bloomberg/dos
Operating profit excluding some items will likely grow by low double digits this year, the Swiss drugmaker said in a statement, raising its forecast for a second time from a prior estimate of high single-digits gains. The stock rose as much as 4% in Zurich trading.
Novartis has worked on severing itself from Sandoz for almost a year to hone its focus on more lucrative innovative medicines. The spinoff will take place in the fourth quarter if shareholders endorse it at a meeting on September 15, the company said.
The drugmaker is in flux as Chief Executive Officer Vas Narasimhan sheds its less profitable projects and divisions to boost growth. The CEO has wrestled with research setbacks even as he reorganized the drugmaker and slashed jobs.
After seeing Novartis deliver strong results from breast cancer drug Kisqali in a clinical trial, investors are now turning their focus to the company’s operating performance, Barclays Plc analyst Emily Field wrote in a note.
Meanwhile, potential generic competitors are on the horizon for Novartis’s biggest drug, heart medicine Entresto. A US judge ruled a patent invalid this month, but the drug probably won’t face generic competition before mid-2025, Chief Financial Officer Harry Kirsch said in a conference call with reporters.
More
More
Swiss pharma reckons with its past, present and future
This content was published on
This is the story of how making drugs helped turn a small, mountainous country into an industry titan, and what the pandemic means for its future.
All of Sandoz will get spun off, Novartis said Tuesday. The stock will trade on the Swiss exchange, with an American Depositary Receipt program in the US.
Earnings per share excluding some items rose to $1.83 last quarter, exceeding analysts’ estimates of $1.70.
Popular Stories
More
Multinational companies
Azeri fossil-fuel cash cow brings controversy to Switzerland
Is artificial intelligence an advantage or a disadvantage for workers?
What is your experience with AI at work? Have you already used it? Has it helped you work better? Or has it caused you more stress, more work or caused you to lose your job? Tell us about your experiences!
Swiss price watchdog slams excessive prices for generic medicines
This content was published on
The cheapest generic medicines available in Switzerland are more than twice as expensive as in other countries, according to a study by the Swiss price watchdog.
Nature should not figure in net zero calculations: academic study
This content was published on
The natural removal of CO2 from the atmosphere by forests or oceans should not be included in the net-zero balance of climate protection measures, argue researchers.
This content was published on
None of the 15 major Swiss retail banks is meeting international climate and biodiversity targets, according to a ranking by WWF Switzerland.
This content was published on
Nestlé's new CEO Laurent Freixe, has presented plans for the future of the world's largest food company, after his first few weeks in office.
Swiss foreign minister calls on Moscow to end Ukraine war
This content was published on
It's high time Moscow ended its war against Ukraine, Swiss foreign minister Ignazio Cassis tells the UN Security Council.
This content was published on
The only alternative to the UN Palestinian agency’s work in Gaza is to allow Israel to run services there, Philippe Lazzarini, UNRWA Commissioner-General, told reporters in Geneva on Monday.
Study reveals food culture differences between Switzerland and neighbours
This content was published on
Three-quarters of Swiss people consider eating to be a pleasurable, social activity, a new survey reveals. Healthy eating, however, plays a much less important role, it found.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.